Department of Oncology 5073, The Finsen Center, Rigshospitalet, 9 Blegdamsvej, 2100 Copenhagen, Denmark.
Cancer Chemother Pharmacol. 2012 Feb;69(2):573-6. doi: 10.1007/s00280-011-1794-6. Epub 2011 Dec 6.
Dexrazoxane is an established treatment option in extravasation of the classic anthracyclines such as doxorubicin, epirubicin, and daunorubicin. However, it is not known whether the protection against the devastating tissue injuries extends into extravasation with new types of anthracyclines, the anthracenediones, or the liposomal pegylated anthracycline formulations. We therefore tested the antidotal efficacy of dexrazoxane against extravasation of amrubicin, mitoxantrone, and liposomal pegylated doxorubicin in mice.
A total of 80 female B6D2F1 mice were tested in an established mouse extravasation model. The mice had experimental extravasations of amrubicin, mitoxtanrone, and Caelyx and were immediately hereafter treated with systemic dexrazoxane or saline.
Systemic treatment with dexrazoxane resulted in significant protection against extravasation injuries from all three drugs. Moreover, the vesicant potential of the three test drugs was weaker than seen in previous experiments with the classic anthracyclines.
右雷佐生是治疗蒽环类药物外渗的一种既定治疗方案，如多柔比星、表柔比星和柔红霉素。然而，对于新型蒽环类药物、蒽环二酮或脂质体结合型多柔比星制剂的外渗，其是否具有预防破坏性组织损伤的作用尚不清楚。因此，我们在小鼠模型中检测了右雷佐生对抗氨柔比星、米托蒽醌和脂质体结合型多柔比星外渗的解毒疗效。
共 80 只 B6D2F1 雌性小鼠在已建立的小鼠外渗模型中进行了测试。将小鼠进行氨柔比星、米托蒽醌和 Caelyx 的实验性外渗，此后立即用系统给予右雷佐生或生理盐水进行治疗。
系统给予右雷佐生治疗可显著预防三种药物引起的外渗损伤。此外，三种测试药物的刺激性比以前用经典蒽环类药物进行的实验中观察到的要弱。
